花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价

智通财经03-10

智通财经APP获悉，花旗集团将Hims & Hers Health(HIMS.US)的评级由"卖出"上调至"中性"，同时将目标价从13.25美元大幅上调至24美元——以3月9日收盘价计算，该目标价对应约8%的上涨空间。此次调整主要基于公司近期与诺和诺德(NVO.US)达成的一项关键协议：通过代理销售诺和诺德旗下用于减重及2型糖尿病治疗的GLP-1类药物，Hims & Hers Health显著降低...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618147987?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-10 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618147987","market":"us","top_or_hot":-1,"title":"花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，花旗集团将Hims & Hers Health(HIMS.US)的评级由\"卖出\"上调至\"中性\"，同时将目标价从13.25美元大幅上调至24美元——以3月9日收盘价计算，该目标价对应约8%的上涨空间。此次调整主要基于公司近期与诺和诺德(NVO.US)达成的一项关键协议：通过代理销售诺和诺德旗下用于减重及2型糖尿病治疗的GLP-1类药物，Hims & Hers Health显著降低...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1412108.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 16:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1412108.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，花旗集团将Hims & Hers Health(HIMS.US)的评级由\"卖出\"上调至\"中性\"，同时将目标价从13.25美元大幅上调至24美元——以3月9日收盘价计算，该目标价对应约8%的上涨空间。此次调整主要基于公司近期与诺和诺德(NVO.US)达成的一项关键协议：通过代理销售诺和诺德旗下用于减重及2型糖尿病治疗的GLP-1类药物，Hims & Hers Health显著降低...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1412108.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1412108.html","article_id":"2618147987","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618147987","pubTimestamp":1773130046,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4504":"桥水持仓","BK4559":"巴菲特持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMS":"Hims & Hers Health Inc.","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4007":"制药","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4207":"综合性银行","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4196":"保健护理服务","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVOX":"2倍做多NVO ETF-Defiance","LU0106831901.USD":"贝莱德世界金融基金A2","BK4585":"ETF&股票定投概念","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4532":"文艺复兴科技持仓","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","BK4599":"减肥药","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","HIYY":"YieldMax HIMS Option Income Strategy ETF","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4534":"瑞士信贷持仓","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4566":"资本集团","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC"},"translate_title":"Citi Upgrades Hims & Hers Health (HIMS.US) to Neutral Bullish on Compliance Premium Under Novo Nordisk Deal","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMY":0.6,"NVOX":0.6,"HMYY":0.6,"NVOH":0.6,"HIMZ":0.6,"HIYY":0.6,"HIMS":1.96},"content_text":"智通财经APP获悉，花旗集团将Hims & Hers Health(HIMS.US)的评级由\"卖出\"上调至\"中性\"，同时将目标价从13.25美元大幅上调至24美元——以3月9日收盘价计算，该目标价对应约8%的上涨空间。此次调整主要基于公司近期与诺和诺德(NVO.US)达成的一项关键协议：通过代理销售诺和诺德旗下用于减重及2型糖尿病治疗的GLP-1类药物，Hims & Hers Health显著降低了此前市场所担忧的多种业务风险，包括产品管线单一性、市场竞争压力及合规不确定性等核心问题。花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这种从销售“复合仿制版”向“官方合作伙伴”的身份转变，不仅极大增强了其业务的可持续性，也使其能够更深度地渗透利润丰厚的减重医疗市场。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。市场投资者普遍认为，诺和诺德选择利用 Hims 强大的远程医疗渠道和品牌影响力，将加速其减肥药产品在消费者端的普及率，而 Hims & Hers 也借此确立了其在数字医疗领域的领导地位。尽管Hims & Hers Health通过其渠道销售Wegovy和Ozempic的具体定价尚未对外披露，但分析师Daniel Grosslight预测，这两款药物的月均售价将比诺和诺德官方NovoCare平台的现金自付价格高出约100美元。这一溢价主要源于Hims & Hers提供的增值服务组合——客户在购药同时可获得专业医疗团队支持、个性化营养方案及运动指导等配套服务，形成“药品+服务”的捆绑价值。与此同时，Grosslight警示了该合作协议中的潜在风险条款：根据协议要求，Hims & Hers须停止自行大规模配制司美格鲁肽(即Wegovy和Ozempic的核心活性成分)。此项限制可能对其收入结构造成显著冲击，导致公司营业收入及调整后EBITDA(税息折旧及摊销前利润)出现大幅下滑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,rating","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618147987","isCrawlerRequest":true}